Key result
The REN C-5312T polymorphism, but not C-5434T, was associated with significantly higher serum angiotensin I levels both at baseline and after 5 months of ARB treatment in hypertensive patients.
Why the study?
Does angiotensin II receptor blocker treatment increase serum angiotensin I levels differently based on REN C-5312T and C-5434T polymorphisms in hypertensive patients?
Observational (n=46)
No
Does angiotensin II receptor blocker treatment increase serum angiotensin I levels differently based on REN C-5312T and C-5434T polymorphisms in hypertensive patients?
Absolute Event Rate: 43.2% vs 37.4%
p-value: p=0.008
The REN C-5312T polymorphism, but not C-5434T, is associated with increased serum angiotensin I levels both at baseline and after 5 months of ARB treatment in hypertensive patients.
REN C-5312T may influence ARB response; hypothesis-generating, does not support genotyping in hypertension.
Renin distal enhancer plays a crucial role in regulating renin gene (REN) expression. REN C-5312T enhancer polymorphism increased enhancer activity. REN C-5434T was also identified which supposed to part of enhancer region. Therefore, this study aimed to investigate contribution of both C-5312T and C-5434T to serum angiotensin I in response to angiotensin II receptor blockers (ARB). C-5312T was identified in 46 hypertensive patients by using multiplex polymerase chain reaction (PCR), while C-5434T by using PCR-restiction fragment length of polymorphism (RFLP). Angiotensin I was measured using enzyme linked immunosorbent assay (ELISA). A significant difference of baseline angiotensin I was observed between -5312CC and -5312CT/TT (p=0.038) as well as the angiotensin I after 5 months of ARB treatment (p=0.008) in -5434CT/TT population, but not REN C-5434T. In conclusion, C-5312T resulted in increased mRNA renin level as consequence of higher enhancer activity not only at the baseline but also after 5 months ARB treatment.
No takes yet. Share an insight, caveat, or question.
Rohman et al. (2016) conducted an observational in Hypertension (n=46). REN C-5312T polymorphism (-5312 CT/TT genotype) vs. REN -5312 CC genotype was evaluated on Serum angiotensin I level after 5 months of ARB treatment in the -5434CT/TT population (p=0.008). The REN C-5312T polymorphism, but not C-5434T, was associated with significantly higher serum angiotensin I levels both at baseline and after 5 months of ARB treatment in hypertensive patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: